Hi uval, there doesn`t appear to have been any new info released on the subject since the announcement that you`re referring to from Merck on 19th April-
They didn`t give any indication that they would be doing further studies, but we`ll wait and see what turns up in future announcements.
All the best ~ Jill xx
Uval951 said
Jul 2, 2012
A few months ago the forum discussed the anemia management by ribaverin dose reductions and how it lowers SVR chance. Later the Mercks article was published that Victrelistrials show that reducing the dose of ribaverin is just as effective for the treatment of anemia as adding EPO (procrit), meaning there is no need for patients to take an additional drug,......The rates of sustained virologic response (SVR*) were 71 percent for both those patients whose anemia was managed by ribavirin dose reduction (178/249) and those patients whose anemia was managed by the addition of erythropoietin (EPO) (178/251). The rates of relapse were identical at 10 percent in both groups". Unfortunately, Merck investigated only naïve patient and not relapsed. There are no data about fibroses/ cirrhosis levels of patients too.
Does someone have more or fresh information about the issue?
-- Edited by Uval951 on Monday 2nd of July 2012 10:53:18 PM
Hi uval, there doesn`t appear to have been any new info released on the subject since the announcement that you`re referring to from Merck on 19th April-
http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2012_0419.html
They didn`t give any indication that they would be doing further studies, but we`ll wait and see what turns up in future announcements.
All the best ~ Jill xx
A few months ago the forum discussed the anemia management by ribaverin dose reductions and how it lowers SVR chance. Later the Mercks article was published that Victrelis trials show that reducing the dose of ribaverin is just as effective for the treatment of anemia as adding EPO (procrit), meaning there is no need for patients to take an additional drug,......The rates of sustained virologic response (SVR*) were 71 percent for both those patients whose anemia was managed by ribavirin dose reduction (178/249) and those patients whose anemia was managed by the addition of erythropoietin (EPO) (178/251). The rates of relapse were identical at 10 percent in both groups". Unfortunately, Merck investigated only naïve patient and not relapsed. There are no data about fibroses/ cirrhosis levels of patients too.
Does someone have more or fresh information about the issue?
-- Edited by Uval951 on Monday 2nd of July 2012 10:53:18 PM